Achieving a Maximally Tolerated β-Blocker Dose in Heart Failure Patients: Is There Room for Improvement?

Journal of the American College of Cardiology

Volumn 69, Issue 20, 2017, Pages 2542-2550

  Bhatt, Ankeet S ^a   DeVore, Adam D ^a,b   DeWald, Tracy A ^a   Swedberg, Karl ^c,d   Mentz, Robert J ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

beta antagonists; chronic heart failure; dosing; heart rate

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; METOPROLOL SUCCINATE; NEBIVOLOL; PLACEBO; TIMOLOL;

ADRENERGIC SYSTEM; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG TOLERABILITY; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEART RATE; HOSPITALIZATION; HUMAN; MAXIMUM TOLERATED DOSE; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; CLASSIFICATION; DOSE RESPONSE; DRUG EFFECTS; HEART FAILURE; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART FAILURE; HEART RATE; HUMANS; MAXIMUM TOLERATED DOSE; TREATMENT OUTCOME;

EID: 85019237373     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2017.03.563     Document Type: Review

References (55)

1. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353 (1999), 9–13.
2. Packer, M., Bristow, M.R., Cohn, J.N., et al., U.S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334 (1996), 1349–1355.
3. Packer, M., Coats, A.J.S., Fowler, M.B., et al., Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 (2001), 1651–1658.
4. Poole-Wilson, P.A., Swedberg, K., Cleland, J.G.F., et al., COMET Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362 (2003), 7–13.
5. Packer, M., Fowler, M.B., Roecker, E.B., et al., Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure. results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study. Circulation 106 (2002), 2194–2199.
6. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 (1999), 2001–2007.
7. Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 62 (2013), e147–e239.
8. Heart Failure Society of America. HFSA 2010 comprehensive heart failure practice guideline. J Card Fail 16 (2010), e1–e194.
9. McMurray, J.J.V., Adamopoulos, S., Anker, S.D., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Eur Heart J 33 (2012), 1787–1847.
10. Ponikowski, P., Voors, A.A., Anker, S.D., et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur J Heart Fail 18 (2016), 891–975.
11. Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 68 (2016), 1476–1488.
12. Swedberg, K., Komajda, M., Böhm, M., et al., SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376 (2010), 875–885.
13. Mann, D.L., Bristow, M.R., Mechanisms and models in heart failure: the biomechanical model and beyond. [Published correction appears in Circulation 2005;112:e75] Circulation 111 (2005), 2837–2849.
14. Lymperopoulos, A., Rengo, G., Koch, W.J., Adrenergic nervous system in heart failure: pathophysiology and therapy. Circ Res 113 (2013), 739–753.
15. Silke, B., Beta-blockade in CHF: pathophysiological considerations. Eur Heart J Suppl 8:Suppl C (2006), C13–C18.
16. Rockman, H.A., Koch, W.J., Lefkowitz, R.J., Seven-transmembrane-spanning receptors and heart function. Nature 415 (2002), 206–212.
17. Bristow, M.R., β-Adrenergic receptor blockade in chronic heart failure. Circulation 101 (2000), 558–569.
18. Flather, M.D., Shibata, M.C., Coats, A.J., et al., SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26 (2005), 215–225.
19. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 344 (2001), 1659–1667.
20. Talameh, J.A., Lanfear, D.E., Pharmacogenetics in chronic heart failure: new developments and current challenges. Curr Heart Fail Rep 9 (2012), 23–32.
21. Azuma, J., Nonen, S., Chronic heart failure: beta-blockers and pharmacogenetics. Eur J Clin Pharmacol 65 (2009), 3–17.
22. Fonarow, G.C., Abraham, W.T., Albert, N.M., et al. Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure). Am J Cardiol 102 (2008), 1524–1529.
23. DeVore, A.D., Mi, X., Mentz, R.J., et al. Discharge heart rate and β-blocker dose in patients hospitalized with heart failure: findings from the OPTIMIZE-HF registry. Am Heart J 173 (2016), 172–178.
24. Fowler, M.B., Lottes, S.R., Nelson, J.J., et al., COHERE Participant Physicians. β-Blocker dosing in community-based treatment of heart failure. Am Heart J 153 (2007), 1029–1036.
25. Fiuzat, M., Wojdyla, D., Kitzman, D., et al. Relationship of beta-blocker dose with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial. J Am Coll Cardiol 60 (2012), 208–215.
26. Düngen, H.D., Apostolovic, S., Inkrot, S., et al., CIBIS-ELD Investigators and Project Multicentre Trials in the Competence Network Heart Failure. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. Eur J Heart Fail 13 (2011), 670–680.
27. Yancy, C.W., Fonarow, G.C., Albert, N.M., et al. Influence of patient age and sex on delivery of guideline-recommended heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF. Am Heart J 157 (2009), 754–762.e2.
28. Lee, D.S., Tu, J.V., Juurlink, D.N., et al. Risk-treatment mismatch in the pharmacotherapy of heart failure. JAMA 294 (2005), 1240–1247.
29. Tandon, P., McAlister, F.A., Tsuyuki, R.T., et al. The use of β-blockers in a tertiary care heart failure clinic: dosing, tolerance, and outcomes. Arch Intern Med 164 (2004), 769–774.
30. Mentz, R.J., Wojdyla, D., Fiuzat, M., Chiswell, K., Fonarow, G.C., O'Connor, C.M., Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF). Am J Cardiol 111 (2013), 582–587.
31. Butler, J., Arbogast, P.G., BeLue, R., et al. Outpatient adherence to beta-blocker therapy after acute myocardial infarction. J Am Coll Cardiol 40 (2002), 1589–1595.
32. Galatius, S., Gustafsson, F., Atar, D., Hildebrandt, P.R., Tolerability of β-blocker initiation and titration with bisoprolol and carvedilol in congestive heart failure: a randomized comparison. Cardiology 102 (2004), 160–165.
33. Salpeter, S.R., Ormiston, T.M., Salpeter, E.E., Cardioselective β-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med 137 (2002), 715–725.
34. Ansari, M., Shlipak, M.G., Heidenreich, P.A., et al. Improving guideline adherence: a randomized trial evaluating strategies to increase β-blocker use in heart failure. Circulation 107 (2003), 2799–2804.
35. Butler, J., Khadim, G., Belue, R., et al. Tolerability to β-blocker therapy among heart failure patients in clinical practice. J Card Fail 9 (2003), 203–209.
36. McMurray, J.J.V., Packer, M., Desai, A.S., et al., PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371 (2014), 993–1004.
37. Bristow, M.R., Gilbert, E.M., Abraham, W.T., et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 94 (1996), 2807–2816.
38. Fiuzat, M., Wojdyla, D., Pina, I., Adams, K., Whellan, D., O'Connor, C.M., Heart rate or beta-blocker dose? Association with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION Trial. J Am Coll Cardiol HF 4 (2016), 109–115.
39. Lechat, P., Hulot, J.S., Escolano, S., et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 103 (2001), 1428–1433.
40. Simon, T., Mary-Krause, M., Funck-Brentano, C., Lechat, P., Jaillon, P., Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the Cardiac Insufficiency Bisoprolol Study (CIBIS II). Eur Heart J 24 (2003), 552–559.
41. Laskey, W.K., Alomari, I., Cox, M., et al., AHA Get With The Guidelines-Heart Failure Program. Heart rate at hospital discharge in patients with heart failure is associated with mortality and rehospitalization. J Am Heart Assoc, 4, 2015, e001626.
42. Kristal-Boneh, E., Silber, H., Harari, G., Froom, P., The association of resting heart rate with cardiovascular, cancer and all-cause mortality. Eight year follow-up of 3527 male Israeli employees (the CORDIS Study). Eur Heart J 21 (2000), 116–124.
43. Poole-Wilson, P.A., Uretsky, B.F., Thygesen, K., Cleland, J.G., Massie, B.M., Ryden, L., Atlas Study Group. Mode of death in heart failure: findings from the ATLAS trial. Heart 89 (2003), 42–48.
44. Fox, K., Ford, I., Steg, P.G., Tendera, M., Robertson, M., Ferrari, R., BEAUTIFUL Investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 372 (2008), 817–821.
45. Metra, M., Torp-Pedersen, C., Swedberg, K., et al. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. Eur Heart J 26 (2005), 2259–2268.
46. Arnold, R.H., Kotlyar, E., Hayward, C., Keogh, A.M., Macdonald, P.S., Relation between heart rate, heart rhythm, and reverse left ventricular remodelling in response to carvedilol in patients with chronic heart failure: a single centre, observational study. Heart 89 (2003), 293–298.
47. Gullestad, L., Wikstrand, J., Deedwania, P., et al., MERIT-HF Study Group. What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker?: experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF). J Am Coll Cardiol 45 (2005), 252–259.
48. McAlister, F.A., Wiebe, N., Ezekowitz, J.A., Leung, A.A., Armstrong, P.W., Meta-analysis: β-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 150 (2009), 784–794.
49. Cullington, D., Goode, K.M., Clark, A.L., Cleland, J.G., Heart rate achieved or beta-blocker dose in patients with chronic heart failure: which is the better target?. Eur J Heart Fail 14 (2012), 737–747.
50. Thackray, S.D.R., Ghosh, J.M., Wright, G.A., et al. The effect of altering heart rate on ventricular function in patients with heart failure treated with β-blockers. Am Heart J 152 (2006), 713.e9–713.e13.
51. Di Lenarda, A., Remme, W.J., Charlesworth, A., et al., COMET Investigators. Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial). Eur J Heart Fail 7 (2005), 640–649.
52. Jain, A., Mills, P., Nunn, L.M., et al. Success of a multidisciplinary heart failure clinic for initiation and up-titration of key therapeutic agents. Eur J Heart Fail 7 (2005), 405–410.
53. McManus, R.J., Mant, J., Haque, M., et al. Effect of self-monitoring and medication self-titration on systolic blood pressure in hypertensive patients at high risk of cardiovascular disease: the TASMIN-SR randomized clinical trial. JAMA 312 (2014), 799–808.
54. Kennedy, L., Herman, W.H., Strange, P., Harris, A., GOAL A1C Team. Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HbA1c on glycemic control in patients with type 2 diabetes: the Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial. Diabetes Care 29 (2006), 1–8.
55. McManus, R.J., Mant, J., Bray, E.P., et al. Telemonitoring and self-management in the control of hypertension (TASMINH2): a randomised controlled trial. Lancet 376 (2010), 163–172.